Winning the MedTech category, followed by overall ‘Grand Prix’ Start-Up of the Year 2022, was a testament to the hard work going in over the past five years, particularly from our founders and all those who are supporting us on this journey. The expert judges identified our novel technology as answering a global unmet clinical need and recognised the market opportunity. We are excited about the future of our high-potential start-up and the difference we can make in maternal health.

2023 has been extremely positive, with NUA being the only non-US company selected for the prestigious Texas Medical Center Healthtech Accelerator. Further validation and recognition have been achieved through winning the Medtech category for the Global Tech for Good Competition by Empact Ventures and, more recently, a top 10 award at the inaugural MedFemTech Congress in Paris.